Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback

Taking stock of the drug industry, from the lab to the medicine chest

August 16, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Lynne Sladky/AP STAT+ | Pfizer and BioNTech effort to develop Covid-influenza combination vaccine sees setback The shot showed a lower immune response against one type of flu in a Phase 3 clinical trial. By Matthew Herper Opinion: Gilead must be held accountable for the harm caused by 'patent hopping' an HIV treatment Gilead needs to own up — and pay up — for the damage its "patent hopping" caused people living with HIV who took its toxic TFD drug. By Peter Staley To counter mpox, vaccine maker could ramp up by another 8 million doses next year Bavarian Nordic CEO Paul Chaplin told STAT that 2 million doses of Jynneos vaccine could be produced this year, 8 million in 2025, to protect against mpox. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser